ArticleNature2019
Hepatocytes direct the formation of a pro-metastatic niche in the liver.
2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 246 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
246citing papers in PubMed, 2 pooled it
27.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT05504252 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation
METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin
An Exosome-based Liquid Biopsy Signature for Preoperative Identification of Occult Liver Metastasis in Patients With Pancreatic Ductal Adenocarcinoma
Who cites it
246 citing papers in PubMed, 2 syntheses or guidelines pooled it, 411 citations in OpenAlex.
- Impact of chemotherapeutic agents on liver microenvironment: oxaliplatin create a pro-metastatic landscape.Journal of experimental & clinical cancer research : CR · 2023Pooled it
- Therapeutic targeting of STAT3 pathways in pancreatic adenocarcinoma: A systematic review of clinical and preclinical literature.PloS one · 2021Pooled it
- Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients.JCI insight · 2021Trial
- Clinical metastatic cancer from initiation to colonization: emerging challenges and breakthroughs.Oncogene · 2026Review
- Conserved Metastatic Cell States and Spatial Immune Microenvironment Remodeling Define Pancreatic Cancer Liver Metastases.bioRxiv : the preprint server for biology · 2026Article
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies.Cancer research communications · 2026Article
- Article
- Effect of TGFβ-ITGB6 feedback loop on liver metastasis in SMAD4 wild-type pancreatic cancer.Chinese medical journal · 2026Article
- Alprazolam Reduces Inflammatory Cytokine Production in Pancreatic Cancer-Associated Fibroblasts.Cancer research communications · 2026Article
- Hepatocyte-derived LRG1 primes the liver for metastasis and impairs immunotherapy.Cellular & molecular immunology · 2026Article
- High-Dimensional Protein Analysis Uncovers Distinct Immunologic and Stromal Features in Primary and Metastatic Pancreatic Ductal Adenocarcinoma.Cancer research · 2026Article
- Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment.Nature reviews. Cancer · 2026Review
- The unseen architects of metastasis: coagulation factors in pre-metastatic niche development.Cell communication and signaling : CCS · 2026Review
- Hepatocytes functionally reprogrammed by KIAA1199-high colorectal cancer cells favour the accumulation of pro-metastatic Egr1Nature communications · 2026Article
- Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer.Scientific reports · 2026Article
- Fibroblast STAT3 Activation Drives Organ-Specific Premetastatic Niche Formation.Cancer research · 2026Article
- Cancer metastasisFrontiers in bioengineering and biotechnology · 2026Review
186 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
29 authors at 5 institutions in 1 country.
Jae W LeeAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Meredith L StoneAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Paige M PorrettDivision of Transplant Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Stacy K ThomasAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Chad A KomarAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Joey H LiAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Devora DelmanAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Kathleen GrahamAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Whitney L GladneyAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Xia HuaAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Taylor A BlackAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Austin L ChienAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Krishna S MajmundarAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Jeffrey C ThompsonAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Stephanie S YeeAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Mark H O'HaraAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Charu AggarwalAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Dong XinDivision of Transplant Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abraham ShakedDivision of Transplant Surgery, Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mingming GaoDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA.
Dexi LiuDepartment of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA.
Mitesh J BoradMayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA.
Ramesh K RamanathanMayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA.
Erica L CarpenterAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Ailing JiDepartment of Internal Medicine, University of Kentucky, Lexington, KY, USA.
Maria C de BeerSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA.
Frederick C de BeerDepartment of Internal Medicine, University of Kentucky, Lexington, KY, USA.
Nancy R WebbSaha Cardiovascular Research Center, University of Kentucky, Lexington, KY, USA.
Gregory L BeattyAbramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. gregory.beatty@uphs.upenn.edu.
University of Pennsylvania · USUniversity of Kentucky · USUniversity of Georgia · USMayo Clinic in Florida · USWinnMed · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MTRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI Ken Hashigiwa Cadwell · 1997 to 2026
$32.5MHEMATOLOGY CLINICAL RESEARCH TRAINING PROGRAMT32HL007439 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI LAWRENCE F BRASS, PETER S KLEIN · 1985 to 2026
$17.1MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MTargeting the liver for immunotherapy in pancreatic cancerR01CA197916 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Gregory L Beatty · 2016 to 2026
$3.7MSerum Amyloid A, Inflammasome Activation, and Abdominal Aortic AneurysmsR01HL134731 · NHLBI · UNIVERSITY OF KENTUCKY · PI DE BEER, FREDERICK C., WEBB, NANCY R · 2017 to 2020
$2.1MA role for macrophage phenotype in regulating metastasis in pancreatic carcinomaF30CA196106 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LEE, JAE WON · 2015 to 2016
$95kNCI NIH HHS F30 CA196106NCI NIH HHS P30 CA016520NCI NIH HHS R01 CA197916NCI NIH HHS T32 CA009140NHLBI NIH HHS R01 HL134731NHLBI NIH HHS T32 HL007439NIDDK NIH HHS P30 DK050306
Abstract
The liver is the most common site of metastatic disease
Indexed as
Neoplasm MetastasisTumor MicroenvironmentAnimalsCarcinoma, Pancreatic DuctalColorectal NeoplasmsFemaleHepatocytesInterleukin-6LiverLiver NeoplasmsMaleMicePancreatic NeoplasmsSerum Amyloid A ProteinSTAT3 Transcription FactorInterleukin-6Serum Amyloid A ProteinStat3 protein, mouseSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05504252ClinicalTrials.gov
NCT07224802ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.